Pontificia Universidade Catolica de Sao Paulo

Quick facts

Marketed products

• Pneumoperitoneum pressure 10 mmHg · Infectious Disease
• Pneumoperitoneum pressure 14 mmHg
• Reversal of moderate neuromuscular blockade
• Reversal of superficial neuromuscular blockade · Anesthesiology
  This drug reverses neuromuscular blockade by antagonizing the effects of neuromuscular blocking agents at the neuromuscular junction.
• Sevoflurane - Neostigmine 30 · Anesthesiology
  This is a combination of sevoflurane (a volatile anesthetic) and neostigmine (a cholinesterase inhibitor) used to maintain anesthesia and reverse neuromuscular blockade.
• Sevoflurane - Neostigmine 50
• Sevoflurane - Neostigmine 70 · Anesthesiology
  This is a combination of sevoflurane (a volatile anesthetic) and neostigmine (a cholinesterase inhibitor) used to maintain anesthesia and reverse neuromuscular blockade.
• TIVA - Neostigmine 30
• TIVA - Neostigmine 50 · Neurology
  Neostigmine inhibits acetylcholinesterase, increasing acetylcholine levels at the neuromuscular junction to enhance muscle contraction.
• TIVA - Neostigmine 70 · Neurology
  Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction and in the central nervous system.
• Two-step reversal · Toxicology
  Two-step reversal is a drug that reverses the effects of a specific toxin.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pontificia Universidade Catolica de Sao Paulo portfolio CI brief
• Pontificia Universidade Catolica de Sao Paulo pipeline updates RSS